Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.55 |
| ▸ | HTR2C | P28335 | 6/20 | 0.55 |
| ▸ | DRD2 | P14416 | 4/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.45 |
| ▸ | OGFRL1 | Q5TC84 | 5/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL735588 | 0.99 | HTR2A (0.55) | HTR2AHTR2CDRD2OPRM1OPRL1 | |
| SCHEMBL735511 | 0.93 | HTR2A (0.46) | HTR2AHTR2CDRD2OPRM1OPRL1 | |
| SCHEMBL734860 | 0.92 | HTR2A (0.44) | HTR2AHTR2CDRD2OPRM1OPRL1 | |
| SCHEMBL733706 | 0.90 | OPRM1 (0.47) | HTR2AHTR2CDRD2OPRM1OPRL1 | |
| SCHEMBL735995 | 0.89 | OPRM1 (0.46) | HTR2AHTR2CDRD2OPRM1OPRL1 | |
| SCHEMBL735786 | 0.89 | OPRM1 (0.42) | HTR2AHTR2CDRD2OPRM1OPRL1 | |
| Citric Acid SCHEMBL3165180 | 0.89 | HTR2A (0.45) | HTR2AHTR2CDRD2OPRM1OPRL1 | |
| SCHEMBL735977 | 0.88 | OPRM1 (0.41) | HTR2AHTR2CDRD2OPRM1OPRL1 | |
| SCHEMBL735054 | 0.88 | KDM4E (0.45) | HTR2AHTR2CDRD2OPRM1OPRL1 | |
| SCHEMBL735512 | 0.86 | OPRM1 (0.44) | HTR2AHTR2CDRD2OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044016-B1 | 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1-AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM | GRUENENTHAL GMBH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-8138187-B2 | Substituted heteroaryl derivatives | GRUENENTHAL GMBH (DE) | 2012-03-20 | — | — | US | disclosed |
| US-20100009986-A1 | SUBSTITUTED HETEROARYL DERIVATIVES | GRUNENTHAL GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009986-A1 | SUBSTITUTED HETEROARYL DERIVATIVES | CYP3A43, HMGCR, ABCG2 | HTR2A 238/4885HTR2C 118/4885DRD2 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.